Role of Interaction between Zinc and Amyloid Beta in Pathogenesis of Alzheimer’s Disease

[1]  S. Kozin,et al.  Development of Peptide Biopharmaceuticals in Russia , 2022, Pharmaceutics.

[2]  A. Makarov,et al.  Zn-dependent β-amyloid Aggregation and its Reversal by the Tetrapeptide HAEE , 2023, Aging and disease.

[3]  Blaine R. Roberts,et al.  Quantification of N-terminal amyloid-β isoforms reveals isomers are the most abundant form of the amyloid-β peptide in sporadic Alzheimer’s disease , 2021, Brain communications.

[4]  T. Tzounopoulos,et al.  The Function and Regulation of Zinc in the Brain , 2021, Neuroscience.

[5]  S. Schilling,et al.  Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology , 2020, Alzheimer's research & therapy.

[6]  K. Kornfeld,et al.  Zinc homeostasis and signaling in the roundworm C. elegans. , 2020, Biochimica et biophysica acta. Molecular cell research.

[7]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2020 , 2020, Alzheimer's & dementia.

[8]  A. Grabrucker,et al.  Concentrations of Essential Trace Metals in the Brain of Animal Species—A Comparative Study , 2020, Brain sciences.

[9]  M. Raghunath,et al.  Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease , 2020, Current neuropharmacology.

[10]  2020 Alzheimer's disease facts and figures , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[11]  S. Papageorgiou,et al.  Current and Future Treatments in Alzheimer Disease: An Update , 2020, Journal of central nervous system disease.

[12]  Chaur-Jong Hu,et al.  Clinical trials of new drugs for Alzheimer disease , 2020, Journal of Biomedical Science.

[13]  B. Polis,et al.  A New Perspective on Alzheimer’s Disease as a Brain Expression of a Complex Metabolic Disorder , 2019 .

[14]  A. Makarov,et al.  The Convergence of Alzheimer’s Disease Pathogenesis Concepts , 2019, Molecular Biology.

[15]  C. Sigurdson,et al.  Cryo-EM structure and polymorphism of Aβ amyloid fibrils purified from Alzheimer’s brain tissue , 2019, Nature Communications.

[16]  D. Holtzman,et al.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.

[17]  C. Jack,et al.  “Alzheimer's disease” is neither “Alzheimer's clinical syndrome” nor “dementia” , 2019, Alzheimer's & Dementia.

[18]  Douglas Galasko,et al.  Alzheimer's disease: The right drug, the right time , 2018, Science.

[19]  A. Makarov,et al.  Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects , 2018, Biochemistry (Moscow).

[20]  Alexander A. Makarov,et al.  Phosphorylation of the Amyloid-Beta Peptide Inhibits Zinc-Dependent Aggregation, Prevents Na,K-ATPase Inhibition, and Reduces Cerebral Plaque Deposition , 2018, Front. Mol. Neurosci..

[21]  Mathias Jucker,et al.  Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases , 2018, Nature Neuroscience.

[22]  C. Soto,et al.  Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases , 2018, Nature Neuroscience.

[23]  A. Makarov,et al.  Intravenously Injected Amyloid-β Peptide With Isomerized Asp7 and Phosphorylated Ser8 Residues Inhibits Cerebral β-Amyloidosis in AβPP/PS1 Transgenic Mice Model of Alzheimer’s Disease , 2018, Front. Neurosci..

[24]  A. Makarov,et al.  Enalaprilat Inhibits Zinc-Dependent Oligomerization of Metal-Binding Domain of Amyloid-beta Isoforms and Protects Human Neuroblastoma Cells from Toxic Action of these Isoforms , 2018, Molecular Biology.

[25]  M. Mesulam,et al.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. , 2018, Brain : a journal of neurology.

[26]  Maya L. Gosztyla,et al.  The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease , 2018, Front. Aging Neurosci..

[27]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[28]  A. Mudher,et al.  Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease , 2018, Acta neuropathologica communications.

[29]  C. Masters,et al.  A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain , 2017, Nature Reviews Neurology.

[30]  C. Masters,et al.  A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain , 2017, Nature Reviews Neurology.

[31]  S. Radford,et al.  Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation , 2017, Biophysical Reviews.

[32]  S. Strittmatter,et al.  Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity. , 2017, Cold Spring Harbor perspectives in medicine.

[33]  A. Makarov,et al.  Chemical modifications of amyloid-β(1-42) have a significant impact on the repertoire of brain amyloid-β(1-42) binding proteins. , 2016, Biochimie.

[34]  P. Kapahi,et al.  Zinc Levels Modulate Lifespan through Multiple Longevity Pathways in Caenorhabditis elegans , 2016, PloS one.

[35]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[36]  A. Makarov,et al.  Interplay of histidine residues of the Alzheimer’s disease Aβ peptide governs its Zn-induced oligomerization , 2016, Scientific Reports.

[37]  A. Makarov,et al.  Intracerebral Injection of Metal-Binding Domain of Aβ Comprising the Isomerized Asp7 Increases the Amyloid Burden in Transgenic Mice , 2016, Neurotoxicity Research.

[38]  A. Makarov,et al.  Intracerebral Injection of Metal-Binding Domain of Aβ Comprising the Isomerized Asp7 Increases the Amyloid Burden in Transgenic Mice , 2016, Neurotoxicity Research.

[39]  P. Tsvetkov,et al.  Peripherally applied synthetic tetrapeptides HAEE and RADD slow down the development of cerebral β-amyloidosis in AβPP/PS1 transgenic mice. , 2016, Journal of Alzheimer's disease : JAD.

[40]  Xi Chen,et al.  Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases , 2015, Chemistry Central Journal.

[41]  E. L. Guenther,et al.  The Amyloid State of Proteins , 2015 .

[42]  P. Tsvetkov,et al.  The English (H6R) familial Alzheimer's disease mutation facilitates zinc-induced dimerization of the amyloid-β metal-binding domain. , 2015, Metallomics : integrated biometal science.

[43]  Chris Li,et al.  Use of Caenorhabditis elegans as a model to study Alzheimer’s disease and other neurodegenerative diseases , 2014, Front. Genet..

[44]  P. Tsvetkov,et al.  Phosphorylation of Ser8 promotes zinc-induced dimerization of the amyloid-β metal-binding domain. , 2014, Molecular bioSystems.

[45]  The Lancet Neurology.  G8 dementia summit: a chance for united action , 2014, The Lancet Neurology.

[46]  Michele Vendruscolo,et al.  Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism , 2013, Proceedings of the National Academy of Sciences.

[47]  P. Tsvetkov,et al.  Peripherally Applied Synthetic Peptide isoAsp7-Aβ(1-42) Triggers Cerebral β-Amyloidosis , 2013, Neurotoxicity Research.

[48]  D. Selkoe,et al.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[49]  Jack A. Tuszynski,et al.  The Zinc Dyshomeostasis Hypothesis of Alzheimer's Disease , 2012, PloS one.

[50]  Mathias Jucker,et al.  The Amyloid State of Proteins in Human Diseases , 2012, Cell.

[51]  M. Jucker,et al.  Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders , 2011, Annals of neurology.

[52]  Menno P. Witter,et al.  A pathophysiological framework of hippocampal dysfunction in ageing and disease , 2011, Nature Reviews Neuroscience.

[53]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[54]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[55]  M. Hoch,et al.  Extracellular phosphorylation of the amyloid β‐peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease , 2011, The EMBO journal.

[56]  P. Tsvetkov,et al.  Zinc-induced dimerization of the amyloid-β metal-binding domain 1-16 is mediated by residues 11-14. , 2011, Molecular bioSystems.

[57]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[58]  Alexander A. Makarov,et al.  Minimal Zn(2+) binding site of amyloid-β. , 2010, Biophysical journal.

[59]  C. Link,et al.  Assaying β-amyloid Toxicity using a Transgenic C. elegans Model , 2010, Journal of visualized experiments : JoVE.

[60]  Ruth Nussinov,et al.  Zinc ions promote Alzheimer Aβ aggregation via population shift of polymorphic states , 2010, Proceedings of the National Academy of Sciences.

[61]  P. Tsvetkov,et al.  Minimal Zn 2þ Binding Site of Amyloid-b , 2010 .

[62]  C. Ewald,et al.  Understanding the molecular basis of Alzheimer’s disease using a Caenorhabditis elegans model system , 2010, Brain Structure and Function.

[63]  B. Barbour,et al.  Zinc at glutamatergic synapses , 2009, Neuroscience.

[64]  K. Takano.  Amyloid β Conformation in Aqueous Environment , 2008 .

[65]  P. Tsvetkov,et al.  Isomerization of the Asp7 Residue Results in Zinc‐Induced Oligomerization of Alzheimer’s Disease Amyloid β(1–16) Peptide , 2008, Chembiochem : a European journal of chemical biology.

[66]  A. Prasad.  Clinical, immunological, anti-inflammatory and antioxidant roles of zinc , 2008, Experimental Gerontology.

[67]  K. Takano.  Amyloid beta conformation in aqueous environment. , 2008, Current Alzheimer research.

[68]  P. Faller,et al.  Amyloid‐Beta Peptide Forms Monomeric Complexes With CuII and ZnII Prior to Aggregation , 2007 .

[69]  P. Faller,et al.  Amyloid-beta peptide forms monomeric complexes with Cu(II) and Zn(II) prior to aggregation. , 2007, Chembiochem : a European journal of chemical biology.

[70]  Antonio Lanzirotti,et al.  Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. , 2006, Journal of structural biology.

[71]  A. Mazur,et al.  Structural Changes of Region 1-16 of the Alzheimer Disease Amyloid β-Peptide upon Zinc Binding and in Vitro Aging* , 2006, Journal of Biological Chemistry.

[72]  Antonio Rosato,et al.  Counting the zinc-proteins encoded in the human genome. , 2006, Journal of proteome research.

[73]  M. Przybylski,et al.  Zinc binding agonist effect on the recognition of the β-amyloid (4–10) epitope by anti-β-amyloid antibodies , 2004 .

[74]  K. Tew,et al.  Trace elements in human physiology and pathology: zinc and metallothioneins. , 2003, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[75]  J. Tabet,et al.  Zinc binding properties of the amyloid fragment Aβ(1–16) studied by electrospray-ionization mass spectrometry , 2003 .

[76]  Math P. Cuajungco,et al.  Zinc takes the center stage: its paradoxical role in Alzheimer’s disease , 2003, Brain Research Reviews.

[77]  G. H. Hoa,et al.  Zinc binding to Alzheimer's Abeta(1-16) peptide results in stable soluble complex. , 2001, Biochemical and biophysical research communications.

[78]  D. Westaway,et al.  Examining the zinc binding site of the amyloid-β peptide , 2000 .

[79]  T. Shirasawa,et al.  Isoaspartate formation and neurodegeneration in Alzheimer's disease. , 2000, Archives of biochemistry and biophysics.

[80]  H. Takeuchi,et al.  Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. , 2000, Biochemistry.

[81]  Sang Won Suh,et al.  Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains , 2000, Brain Research.

[82]  D. Westaway,et al.  Examining the zinc binding site of the amyloid-beta peptide. , 2000, European journal of biochemistry.

[83]  Philip Scheltens,et al.  Visual assessment of medial temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry , 1999, Psychiatry Research: Neuroimaging.

[84]  C. Barrow,et al.  Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. , 1999, Biochemistry.

[85]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[86]  Mark S. Shearman,et al.  Amyloid-β Hypothesis of Alzheimer’s Disease , 1998 .

[87]  H. Braak,et al.  Staging of Alzheimer-related cortical destruction. , 1997, International psychogeriatrics.

[88]  C. Masters,et al.  Rapid induction of Alzheimer A beta amyloid formation by zinc. , 1994, Science.

[89]  R. Tanzi,et al.  Modulation of A beta adhesiveness and secretase site cleavage by zinc. , 1994, The Journal of biological chemistry.

[90]  M J Ball,et al.  Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. , 1993, The Journal of biological chemistry.

[91]  T. Smart,et al.  A physiological role for endogenous zinc in rat hippocampal synaptic neurotransmission , 1991, Nature.

[92]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.